UK-based Monument Therapeutics has joined forces with the Foundation for the National Institutes of Health (FNIH), US, to ...

Cambridge Cognition said on Tuesday that Monument Therapeutics, in which it holds a 20% stake, has partnered with the Foundation for the National Institutes of Health to trial a new treatment for ...

(Alliance News) - Cambridge Cognition Holdings PLC on Tuesday said Monument Therapeutics, in which it holds a 20% stake, has partnered up on the development of a novel treatment for cognitive ...

MANCHESTER, UNITED KINGDOM, June 23, 2025 / EINPresswire.com / -- Monument Therapeutics, a precision neuroscience company, today announced positive topline results from its Phase I clinical trial ...

Sheryl Caswell, Chief Development Officer of Monument Therapeutics, added, "The initiation of our Phase I study for MT1988 marks a significant milestone in its clinical development.

Dr Sand's extensive expertise in schizophrenia drug development has already significantly contributed to Monument's approach in developing MT1988.

Monument's treatment MT1988 is complementary to existing drugs for schizophrenia, including the newly-approved drug Cobenfy, which was originally developed by Karuna Therapeutics and acquired by ...

Monument's treatment MT1988 is complementary to existing drugs for schizophrenia, including the newly-approved drug Cobenfy, which was originally developed by Karuna Therapeutics and acquired by ...